Contributions
Abstract: P318
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Infections with Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV6) have been implicated in multiple sclerosis (MS) onset. Few studies have evaluated the role of viral parameters on MS clinical course.
Objective: We evaluated associations between EBV and HHV6 viral markers and the subsequent hazard of conversion to clinically definite MS (CDMS), relapses and annualised change of Expanded Disability Status Scale (EDSS) post clinically isolated syndrome (CIS).
Method: In a prospective cohort study, we followed a total of 279 cases for at least 5 years post CIS. Serological viral biomarkers were measured at baseline. CDMS and relapse for each person were recorded by in-person reviews and medical record reviews.
Results: Baseline anti-HHV6 IgG was significantly associated with the risk of conversion to CDMS (p=0.05) and most prominent in higher latitudes(Tasmania) (p=0.04). For the relapse analysis, we did not observe a statistical significant association with anti-HHV6 IgG, but when we restricted our analysis to Tasmania this became significant (p=0.03). We observed a weak dose-dependent association between anti-HHV6 IgG and annualised change of EDSS (p=0.10), those with anti-HHV6 IgG≥640 showed a 0.11 increase (p=0.06) when compared to those with anti-HHV6 IgG≤40. Baseline EBV DNA positivity was associated with a faster conversion to CDMS (HR 2.23; p=0.02) in multivariable model, but there was no association with relapses. Other EBV specific immune response such as Epstein-Barr virus nuclear antigen, early antigen (diffuse and restricted, EA-D and EA-R) and viral capsid antigen were not associated with MS progression.
Conclusion: These results suggest a significant association between baseline higher anti-HHV6 IgG and subsequent risk of conversion to CDMS. In the relapse analysis, the association exhibited a latitudinal effect and only influenced those living at higher latitude.
Disclosure: Authors have no relevant disclosures
Abstract: P318
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: Infections with Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV6) have been implicated in multiple sclerosis (MS) onset. Few studies have evaluated the role of viral parameters on MS clinical course.
Objective: We evaluated associations between EBV and HHV6 viral markers and the subsequent hazard of conversion to clinically definite MS (CDMS), relapses and annualised change of Expanded Disability Status Scale (EDSS) post clinically isolated syndrome (CIS).
Method: In a prospective cohort study, we followed a total of 279 cases for at least 5 years post CIS. Serological viral biomarkers were measured at baseline. CDMS and relapse for each person were recorded by in-person reviews and medical record reviews.
Results: Baseline anti-HHV6 IgG was significantly associated with the risk of conversion to CDMS (p=0.05) and most prominent in higher latitudes(Tasmania) (p=0.04). For the relapse analysis, we did not observe a statistical significant association with anti-HHV6 IgG, but when we restricted our analysis to Tasmania this became significant (p=0.03). We observed a weak dose-dependent association between anti-HHV6 IgG and annualised change of EDSS (p=0.10), those with anti-HHV6 IgG≥640 showed a 0.11 increase (p=0.06) when compared to those with anti-HHV6 IgG≤40. Baseline EBV DNA positivity was associated with a faster conversion to CDMS (HR 2.23; p=0.02) in multivariable model, but there was no association with relapses. Other EBV specific immune response such as Epstein-Barr virus nuclear antigen, early antigen (diffuse and restricted, EA-D and EA-R) and viral capsid antigen were not associated with MS progression.
Conclusion: These results suggest a significant association between baseline higher anti-HHV6 IgG and subsequent risk of conversion to CDMS. In the relapse analysis, the association exhibited a latitudinal effect and only influenced those living at higher latitude.
Disclosure: Authors have no relevant disclosures